Cassava Sciences saw the highest growth of 1.99% in patent filings in May and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Cassava Sciences’s patent filings and grants. Buy the databook here.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Cassava Sciences has been focused on protecting inventions in European Patent Office(EPO) with two publications in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent filings with nearly 67% of filings. The European Patent Office(EPO), and United States(US) patent Office are among the top ten patent offices where Cassava Sciences is filings its patents..
Roche could be the strongest competitor for Cassava Sciences
Patents related to rare diseases lead Cassava Sciences's portfolio
Cassava Sciences has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Alzheimer's disease related patents lead Cassava Sciences portfolio followed by chronic traumatic encephalopathy (cte), and traumatic brain injury
Cassava Sciences has highest number of patents in alzheimer's disease followed by chronic traumatic encephalopathy (cte), traumatic brain injury, insulin resistance.
For comprehensive analysis of Cassava Sciences's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

